Xofigo

Chemical Nameradium Ra 223 dichloride
Dosage FormInjection (intravenous; 1,100 kBq/mL (30 microcurie/mL))
Drug ClassRadioactive agents
SystemMale reproductive, Musculoskeletal
CompanyBayer HealthCare Pharmaceuticals Inc.
Approval Year2013

Indication

  • For the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
Last updated on 4/29/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xofigo (radium Ra 223 dichloride) Prescribing Information2013Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Document TitleYearSource
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. 2017European Journal of Nuclear Medicine and Molecular Imaging